MedTrace Logo

Adaptive Stereotactic Radiotherapy for Localized Prostate Cancer

NCT07344844 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-01-15

No results posted yet for this study

Summary

This study evaluates whether adaptive stereotactic body radiotherapy (SBRT) provides dosimetric advantages compared to non-adaptive SBRT in localized prostate cancer. Five low-dose CT scans are performed before each SBRT session to assess anatomical variations (bladder filling, rectal volume) and determine if a dosimetric recalculation would have been required. The study also evaluates cumulative dose to organs at risk, patient-reported quality of life over 24 months, and overall and recurrence-free survival.

Conditions

  • Prostate Cancer (Adenocarcinoma)

Interventions

OTHER

Low-dose CT imaging before each SBRT session

Five low-dose, non-contrast CT scans performed immediately before each SBRT session (≈10 min before treatment) to assess anatomical variations impacting target volume and organ-at-risk dosimetry.

Sponsors & Collaborators

  • Clinique Sainte Clotilde

    lead OTHER

Principal Investigators

  • Youssef Slama · Clinique Sainte Clotilde

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-18
Primary Completion
2029-03-01
Completion
2029-05-01

Countries

  • Reunion

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07344844 on ClinicalTrials.gov